Chromosome Y as A Marker for Sex Discrepancies in Patients With Organ Transplants: A Case Report

Nuria Balaguer
Igenomix Spain Lab S.L.U. Parque tecnológico

Emilia Mateu-Brull
Igenomix Spain Lab S.L.U. Parque tecnológico

Roy Pascal Naja
Igenomix UK Ltd, Surrey Technology Centre

Jara Ben Nagi
The Centre for Reproductive & Genetic Health

Miguel Milán (✉️ miguel.milan@igenomix.com)
Igenomix Spain Lab S.L.U. Parque tecnológico

Case Report

Keywords: NIPT, Bone marrow, cfDNA, sex-discrepancy.

DOI: https://doi.org/10.21203/rs.3.rs-96720/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Organ transplantations cause discrepancy in results from cell-free DNA (cfDNA) testing, but scientific literature is scarce.

**Case:** A 33-year-old gravida underwent cfDNA testing, which showed high levels of Y chromosome (ChrY) in the maternal bloodstream. The ChrY pattern was comparable to an adult male reference. As a result, cfDNA testing was only informative for autosomes. Routine 20-week ultrasound scan showed no structural alterations and the presence of female external genitalia. Post-clinical research revealed that the patient received a bone marrow transplant from a male donor several years before. Fluorescence in situ hybridization showed that 100% of nuclei analysed from the patient’s lymphocytes presented a ChrY.

**Conclusion:** This case demonstrates ChrY can be used as a marker to avoid sex discrepancies in certain patients with organ transplants.

**Background**

Cell-free DNA (cfDNA) testing for chromosomal aneuploidies offers higher sensitivity and specificity for common autosomal chromosomal aneuploidies and sex determination at an earlier gestational age compared to traditional biochemical and sonographic screening(1). As a result, cfDNA testing is widely selected as the first choice for detecting common foetal aneuploidies and determining foetal sex(2). However, health care professionals offering this test must provide comprehensive pre-test prenatal counselling to discuss potential results, including risk of possible discordances between cfDNA results and the ultrasound examination and/or the actual foetal genetic chromosomal constitution(3). These discrepancies may be explained by technical human errors and biological mechanisms. Amongst sources of human errors include blood sample mislabelling, laboratory methodologic limitations, and suboptimal visualization of the external genitalia associated with limited performance of ultrasound imaging at early gestational ages. In turn, biological reasons for discordance include the presence of a vanishing twin, foetal-placental mosaicism for sex chromosome abnormalities, maternal transplant from a male donor, disorders of sexual development, or other foetal abnormalities associated with anomalous or ambiguous external genitalia(4). In this context, we describe herein a case where foetal sex determination by noninvasive prenatal testing (NIPT) versus ultrasound screening was discrepant in a pregnant woman who had a bone marrow transplantation from a male donor.

**Case Presentation**

**Case history**

The patient was a 33-year-old gravida who conceived after in vitro fertilization treatment in September 2019. At 11 weeks of gestation, she underwent cfDNA testing (NACE test, Igenomix, Valencia, Spain) at her request. The native cfDNA testing algorithm indicated a low risk for trisomies in the analysed
chromosomes (13, 18, 21, X, and Y) and a male sex classification. A more detailed analysis of sex chromosomes identified an anomalous normalized chromosome value (NCV) for chromosomes X and Y, compatible with neither a female nor male foetus (NCV_Y = 867.7; NCV_X = − 88.7). Specifically, these values were 10-fold higher (in absolute value) than expected for the foetal fraction (FF) registered (6.4%). To exclude a misdiagnosis due to external contamination or possible artifacts, a new specimen was requested for further analysis. Again, the NCV for chromosomes X and Y were concordant with the first cfDNA testing, compatible with a male sex and with a higher than expected NCV_Y value of 891.6 (Fig. 1A). Since FF can be estimated based on amount of Chr Y(5), we compared FF estimations by two different methodologies: the SeqFF approach(6), and another method based on Chr Y(5). In the first blood sample, SeqFF estimated overall FF of 6.4%, whereas the Y chromosome-based method yielded 73.7%. Similarly, in the second specimen, SeqFF estimation was 8.02%, whereas Y chromosome-based estimation was 75.7%.

Given the data reproducibility, we requested any non-disclosed clinical condition inherent to the patient that could explain our findings. Interestingly, the patient was diagnosed in 2013 with Hodgkin’s lymphoma and underwent nine months of chemotherapy and radiotherapy. Nevertheless, her tumor relapsed in 2014, and it was decided that stem cell transplantation was her best option. Before proceeding with the treatment, she underwent embryo freezing for fertility preservation and cryopreserved seven embryos. In 2015, she had autologous stem cell transplantation, which was unsuccessful. However, soon after, she successfully received a donor stem cell transplant from her brother. In February 2019, she opted for medicated frozen embryo transfer, where just one embryo was transferred. Preimplantation genetic testing for aneuploidies (PGT-A) was not performed before embryo transfer. Foetal anatomy and nuchal translucency assessment showed no abnormality at 12 weeks of gestation. The foetus showed no structural alterations at the routine 20-week ultrasound scan, although female external genitalia were identified. Following discussion of the consulting physician and patient, further investigations were instigated, including fluorescent in situ hybridization (FISH) analysis of chromosomes 18, X, and Y on the white blood cell (WBC) fraction isolated from a second maternal sample. Of 100 total nuclei analysed, 100% showed two signals for chromosome 18 and one signal each for chromosomes X and Y (Fig. 1B). A female infant was delivered at 37 weeks of gestation by elective Caesarean section and weighed 2.2 Kg. There were no reported congenital abnormalities.

**Discussion And Conclusions**

Foetal sex determination can be carried out reliably from seven weeks of gestation using real-time quantitative PCR to identify presence or absence of Y chromosome-specific sequences in maternal plasma(7, 8). Foetal sex also can be reported using cfDNA testing, although it is not considered a primary medical indication. It has been estimated that the overall average sensitivity of using cfDNA to determine foetal sex is 96.6% and overall specificity is 98.9%(9), but these figures may vary depending on the technology and platform used for analysis. Results of cfDNA testing may be discordant with either the ultrasound appearance of external genitalia or PGT-A results for multiple reasons. In this sense, foetal sex discordance rates of 0.0–0.9% have been described(4, 10–12).
While organ transplants are uncommon in women requesting cfDNA testing, transplants have been reported as a source of incorrect foetal sex prediction(3, 13). To date, case reports detailing the clinical aspects surrounding stem cell or organ transplants are scarce. The largest study published to date was performed by Wardrop et al., 2018(14), who discussed 11 NIPT cases with a previous maternal transplant. Specifically, seven of the cases (63.6%) were bone marrow transplants, but only in one case was a sex discrepancy identified with proper follow-up. From these results, the authors concluded that not all tissues/organs equally contribute cfDNA to maternal plasma, with bone marrow transplants having a more significant contribution to contaminating cfDNA.

Similarly, Balslev-Harder et al.(13) reported that the Y chromosome content in maternal blood was high enough to mask the overall fraction of placental-derived DNA in cfDNA. Interestingly, the authors demonstrated that the length distribution of Y chromosome sequence reads could be used to distinguish rare occurrences of maternal Y chromosomal contribution from leukocytes or possible single organ transplants. In our particular case, we detected that the relative percentages of Y chromosome reads obtained in two independent blood samples presented a distribution similar to an adult male reference. Interestingly, those quantities are very similar to the figures described by others, which state that approximately 75% of cfDNA released to maternal circulation is hematopoietic in origin(15). Besides, FISH results suggested that all WBCs isolated from the maternal plasma were XY, confirming that the cause of the foetal sex discordance was attributed to the bone marrow transplant.

Similar cases have also been described in other clinical reports where the transplant was from a different organ than bone marrow. Bianchi et al., 2015(16), described their clinical experience with cfDNA testing for foetal sex chromosomes in a large cohort study. Their study identified a discordant result caused by a kidney transplant from a male donor. Also, in the same year, cfDNA testing of a patient who previously received a renal transplant was negative for chromosomal abnormalities and consistent with a male foetus. However, the foetal anatomy ultrasound at 20 weeks of gestation showed female genitalia, confirmed by the birth of a female baby. More recently, a clinical case in 2018 describing cfDNA testing in a woman recipient of a liver transplant from a male donor suggested that graft-derived cfDNA released into the maternal circulation clouded the cfDNA testing prediction of sex(2).

Therefore, given that in certain organ transplants, the amount of sex chromosomes exceeds the expected for the calculated FF, an alert should arise indicating the existence of contaminating DNA in the bloodstream, with the ability to interfere with the final result of the cfDNA testing. Thus, leading companies should modify their algorithms to detect these kinds of scenarios that prevent obtaining informative results for sex chromosomes in terms of aneuploidy calling and correct sex assignment.

Together, these cases demonstrate that due to possible inconsistencies in the final diagnosis, disclosing the foetal sex by cfDNA testing currently might only be advisable when the pregnant mother has had an organ transplant from a female donor. In the remaining scenarios (male donor or donor with an unknown gender), cfDNA testing should be performed only to analyse aneuploidies for autosomes. Therefore, good pre-test counselling and dynamic communication between the health care practitioner and the laboratory
performing the cfDNA testing is required for proper management of these cases. In addition, with advancement of new technologies, novel algorithms will be developed that can discern the origin of cell-free DNA, enabling us to exclude interfering graft-derived cell-free DNA from analysis(2, 13).

This case brings to light the importance of accurate cfDNA analysis in cases where a previous organ transplant has occurred, not only due to the possible resultant sex discrepancies but also because of the impact this may have on accuracy of foetal sex aneuploidy detection. In this regard, adequate pre-test counselling to discuss test limitations as well as a good quality ultrasound are mandatory to avoid potential misdiagnoses.

**List Of Abbreviations**

- **cfDNA**: cell-free DNA
- **ChrY**: Chromosome Y
- **DNA**: deoxyribonucleic acid
- **FF**: Foetal fraction
- **FISH**: Fluorescence in situ hybridization
- **NCV**: Normalized chromosome value
- **NIPT**: Non-invasive prenatal testing
- **PCR**: Polymerase chain reaction
- **PGTA**: Preimplantation genetic testing for aneuploidies
- **WBC**: White blood cell

**Declarations**

**Ethical approval, consent to participate and for publication**

We declared that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.

I affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Regarding ethical issues, I verify that the authors had access to relevant aggregated study data and other information (such as study protocol, analytic plan and report, validated data table, and clinical study
report) required to understand and report research findings. The authors take responsibility for the presentation and publication of the research findings, have been fully involved at all stages of publication and presentation development, and are willing to take public responsibility for all aspects of the work. All individuals included as authors and contributors who made substantial intellectual contributions to the research, data analysis, and publication or presentation development are listed appropriately. The role of the sponsor in the design, execution, analysis, reporting, and funding is fully disclosed. The authors’ personal interests, financial or non-financial, relating to this research and its publication have been disclosed.

On the other hand, we would like to highlight that we have had permission from all people included in the acknowledgements section to be named in the article. Also, we have obtained a signed consent form from the patient involved in this study. These forms are filed with our records and will be available whenever the journal requires it.

**Availability of data and materials**

The data that support the findings of this study are available from Igenomix, S. L., but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Igenomix, S.L.

**Conflict of interest and financial disclosure**

N.B., E.M., R.P.N., J.B.N., and M.M. are employed by Igenomix, S.L and report no conflicts of interest. The study was financially supported by Igenomix Lab S.L.U.

**Author's contributions**

N.B.: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript; E.M.: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript; R.P.N.: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript; J.B.N: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript; MM: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript.

**Acknowledgements**

The authors thank all the NIPT staff at Igenomix Spain Lab S.L.U. for their technical support. and Fresh Eyes Editing LLC for editing this manuscript.

**References**
1. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol. 2015;45(5):530-8.
2. Neofytou M, Brison N, Van den Bogaert K, Dehaspe L, Devriendt K, Geerts A, et al. Maternal liver transplant: Another cause of discordant fetal sex determination using cell-free DNA. Prenat Diagn. 2018;38(2):148-50.
3. Grati FR. Implications of fetoplacental mosaicism on cell-free DNA testing: a review of a common biological phenomenon. Ultrasound Obstet Gynecol. 2016;48(4):415-23.
4. Dhamankar R, DiNonno W, Martin KA, Demko ZP, Gomez-Lobo V. Fetal Sex Results of Noninvasive Prenatal Testing and Differences With Ultrasonography. Obstet Gynecol. 2020;135(5):1198-206.
5. Milan M, Mateu E, Blesa D, Clemente-Ciscar M, Simon C. Fetal sex determination in twin pregnancies using cell free fetal DNA analysis. Prenat Diagn. 2018.
6. Kim SK, Hannum G, Geis J, Tynan J, Hogg G, Zhao C, et al. Determination of fetal DNA fraction from the plasma of pregnant women using sequence read counts. Prenat Diagn. 2015;35(8):810-5.
7. Iruretagoyena JI, Grady M, Shah D. Discrepancy in fetal sex assignment between cell free fetal DNA and ultrasound. J Perinatol. 2015;35(3):229-30.
8. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA. 2011;306(6):627-36.
9. Wright CF, Wei Y, Higgins JP, Sagoo GS. Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis. BMC Res Notes. 2012;5:476.
10. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014;124(2 Pt 1):210-8.
11. Nicolaides KH, Syngelaki A, del Mar Gil M, Quezada MS, Zinevich Y. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther. 2014;35(3):212-7.
12. Moise KJ, Boring NH, O'Shaughnessy R, Simpson LL, Wolfe HM, Baxter JK, et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn. 2013;33(1):95-101.
13. Balslev-Harder M, Jørgensen FS, Kjaergaard S, Johansen P. The length of Y-chromosomal sequence reads in noninvasive prenatal testing reflect allogeneic bone marrow transplant. Prenat Diagn. 2017;37(8):843-5.
14. Wardrop J, Caldwell S, Boomer T, Almasri E, McCullough R. Whose Y is it anyway? Transplants and NIPT II. integrated genetics, Sequenom; 2018.
15. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503-12.
16. Bianchi DW, Parsa S, Bhatt S, Halks-Miller M, Kurtzman K, Sehnert AJ, et al. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet
Gynecol. 2015;125(2):375-82.